SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) December
7, 2005
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
| 99.1 |
On
December 7, 2005 the Registrant issued the press release titled “Chembio
Diagnostics Hires The Investor Relations Group of New York” included
herein as Exhibit 99.1.
|
ITEM
9.01. Financial Statements and Exhibits
| (c) |
Exhibits.
|
.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date:
December 7, 2005 Chembio
Diagnostics, Inc.
By:
/s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Exhibit
99.1 Press Release
Chembio
Diagnostics Hires The Investor Relations Group of New York
MEDFORD,
NY— (Market Wire) --December 7, 2005-- Chembio Diagnostics, Inc. (OTC
BB:CEMI.OB)
has
hired The Investor Relations Group, Inc. ("IRG") based in New York City to
serve
as its financial communications firm. Chembio develops, manufactures, and
markets point of care medical diagnostic tests for the diagnosis of infectious
diseases and other conditions in both humans and animals.
Chembio
Diagnostics is one of only two U.S. based manufacturers of rapid HIV 1&2
test kits. The treatment goals set forth by UNAIDS’ 3x5 initiative and the
Presidential Emergency Plan for AIDS Relief (the US government’s unprecedented
commitment of $15 billion dollars) will fuel a demand for HIV test kits that
is
estimated to be approximately 500 hundred million worldwide.
Chembio
Diagnostics has significant additional opportunities in world markets for
rapid
testing for Tuberculosis and Chagas Disease, endemic in Latin America afflicting
20 million with an annual fatality of 50,000.
IRG
will
strive to increase investor and media awareness of Chembio Diagnostics within
the U.S. market by introducing the company and its management to pre-qualified
investment professionals and both national and specific industry trade
publications. In the future, U.S. investor inquiries relating to Chembio
Diagnostics can be directed to The Investor Relations Group, New York, NY,
Telephone: (212) 825-3210, Fax (212) 825-3229.
About
Chembio
Chembio
Diagnostics, Inc. (Chembio) possesses expertise in the development and
manufacturing of rapid test products for various infectious diseases, including
HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics,
Inc.
may actually refer to Chembio Diagnostic Systems, Inc.; the 100%-owned
subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock
Road, Medford, NY 11763.
For
more
information on Chembio, go to www.chembio.com
About
The Investor Relations Group, Inc.
The
Investor Relations Group, Inc., (IRG) founded in 1996, represents select
publicly traded companies, with a unique specialization for assisting those
in
the small-cap sector. IRG arranges one-on-one meetings for its portfolio
companies with pre-qualified money managers handling investment portfolios
that
range from $10 million to $10 billion+ selected from its proprietary contact
base of over 33,000 qualified fund managers who have an investing history
in
small cap stocks. IRG is a full-service corporate communications company
offering services for its portfolio companies that include writing all press
releases and shareholder communications and serving as primary contact for
the
investing community. IRG also houses a full-service public relations arm
that
specializes in building awareness of its companies within the financial and
trade media, as well as the public at large. For further information, please
visit the company's website at www.investorrelationsgroup.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve
risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited
to
Chembio's ability to obtain additional financing and the demand for Chembio's
products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated events.
Factors that may impact Chembio's success are more fully disclosed in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.
Contact:
Investor
Relations:
The
Investor Relations Group
James
Carbonara/Vince Daniels
212-825-3210